Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EPRX Eupraxia Pharmaceuticals

Market Closed 10-23 16:00:00 EDT

6.87

-0.72

-9.49%

盘后6.99

+0.12+1.75%

19:30 EDT

High7.61	Low6.70	Vol348.80K
Open7.51	D1 Closing7.59	Amplitude11.99%
Mkt Cap453.92M	Tradable Cap374.55M	Total Shares66.07M
T/O2.41M	T/O Rate0.64%	Tradable Shares54.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EPRX","market":"US","secType":"STK","nameCN":"Eupraxia Pharmaceuticals","latestPrice":6.87,"timestamp":1792785600000,"preClose":7.59,"halted":0,"volume":348796,"hourTrading":{"tag":"盘后","latestPrice":6.99,"preClose":6.87,"latestTime":"19:30 EDT","volume":804,"amount":5619.72,"timestamp":1792798203720,"change":0.12,"changeRate":0.017467,"amplitude":0.017467},"delay":0,"changeRate":-0.09486166007905135,"floatShares":54519016,"shares":66073400,"eps":-0.996725,"marketStatus":"Market Closed","change":-0.72,"latestTime":"10-23 16:00:00 EDT","open":7.51,"high":7.61,"low":6.7,"amount":2409633.62227,"amplitude":0.119895,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.996725,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":7.59,"preHourTrading":{"tag":"盘前","latestPrice":7.69,"preClose":7.59,"latestTime":"08:23 EDT","volume":33,"amount":245.6791062,"timestamp":1792758180569,"change":0.1,"changeRate":0.013175,"amplitude":0.102767},"postHourTrading":{"tag":"盘后","latestPrice":6.99,"preClose":6.87,"latestTime":"19:30 EDT","volume":804,"amount":5619.72,"timestamp":1792798203720,"change":0.12,"changeRate":0.017467,"amplitude":0.017467},"volumeRatio":0.6555502512230108},"requestUrl":"/m/hq/s/EPRX/tweets","defaultTab":"tweets","newsList":[{"id":"2677665149","title":"Eupraxia Pharmaceuticals Launches Conference Roadshow and Analyst Day to Spotlight EP-104GI","url":"https://stock-news.laohu8.com/highlight/detail?id=2677665149","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677665149?lang=en_us&edition=fundamental","pubTime":"2026-10-22 21:22","pubTimestamp":1792675328,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has provided an announcement. On October 22, 2026, Eupraxia Pharmaceuticals announced that its management ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-launches-conference-roadshow-and-analyst-day-to-spotlight-ep-104gi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-launches-conference-roadshow-and-analyst-day-to-spotlight-ep-104gi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677963114","title":"Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2677963114","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677963114?lang=en_us&edition=fundamental","pubTime":"2026-10-22 20:30","pubTimestamp":1792672200,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Oct.  22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/22/3386361/0/en/eupraxia-pharmaceuticals-to-participate-at-upcoming-conferences-and-host-a-virtual-analyst-day.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677061976","title":"Analyst Reiterates Buy on Eupraxia Pharmaceuticals, Sees Attractive Risk-Reward with Unchanged $11 Price Target Ahead of Phase 2b RESOLVE Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2677061976","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677061976?lang=en_us&edition=fundamental","pubTime":"2026-10-21 04:35","pubTimestamp":1792528521,"startTime":"0","endTime":"0","summary":"In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Eupraxia Pharmaceuticals, with a price target of $11.00....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-eupraxia-pharmaceuticals-sees-attractive-risk-reward-with-unchanged-11-price-target-ahead-of-phase-2b-resolve-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-eupraxia-pharmaceuticals-sees-attractive-risk-reward-with-unchanged-11-price-target-ahead-of-phase-2b-resolve-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675531862","title":"Eupraxia Pharmaceuticals: Buy Rating Reaffirmed on Strong Phase 2b Setup and Favorable Risk-Reward After Price Target Cut to $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2675531862","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675531862?lang=en_us&edition=fundamental","pubTime":"2026-10-16 00:55","pubTimestamp":1792083327,"startTime":"0","endTime":"0","summary":"In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Eupraxia Pharmaceuticals, with a price target of $11.00....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/eupraxia-pharmaceuticals-buy-rating-reaffirmed-on-strong-phase-2b-setup-and-favorable-risk-reward-after-price-target-cut-to-11-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/eupraxia-pharmaceuticals-buy-rating-reaffirmed-on-strong-phase-2b-setup-and-favorable-risk-reward-after-price-target-cut-to-11-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675853302","title":"Eupraxia Pharmaceuticals Hits RESOLVE Trial Enrollment Target Ahead of December Interim Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2675853302","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675853302?lang=en_us&edition=fundamental","pubTime":"2026-10-15 22:28","pubTimestamp":1792074495,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an update. On October 12, 2026, Eupraxia Pharmaceuticals reached its target enrollment of 120 p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-hits-resolve-trial-enrollment-target-ahead-of-december-interim-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-hits-resolve-trial-enrollment-target-ahead-of-december-interim-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675827795","title":"Eupraxia Pharmaceuticals Says Phase 2b Trial in Eosinophilic Esophagitis Meets Enrollment Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2675827795","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675827795?lang=en_us&edition=fundamental","pubTime":"2026-10-15 20:46","pubTimestamp":1792068362,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals  said Thursday that it has reached its target enrollment of 120 patients for a phase 2b study of EP-104GI in eosinophilic esophagitis.The company said it has treated its 120th patient in the placebo-controlled trial, which is evaluating doses of 120mg and 160mg of EP-104GI. Interim results are expected in December, Eupraxia said.Eosinophilic esophagitis is an inflammatory-mediated disease, which creates pain and difficulty for patients when swallowing food.Shares of Eupraxia were down 4.4% pre-bell Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674851425","title":"Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2674851425","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674851425?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:00","pubTimestamp":1791547200,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Oct.  09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/09/3378041/0/en/eupraxia-pharmaceuticals-to-present-at-upcoming-american-college-of-gastroenterology-acg-and-united-european-gastroenterology-ueg-medical-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","UBCP","EPRX","BK4107","BK4211","AFG","BK4139","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672046765","title":"Eupraxia Pharmaceuticals Down Nearly 11%, on Pace for Largest Percent Decrease Since September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2672046765","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672046765?lang=en_us&edition=fundamental","pubTime":"2026-10-02 00:14","pubTimestamp":1790871240,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals, Inc.  is currently at $8.10, down $1.00 or 10.99%--On pace for largest percent decrease since Sept. 23, 2025, when it fell 14.89%--Snaps a three day winning streak--Up 7.28% year-to-date--Down 10.99% from its all-time closing high of $9.10 on Sept. 30, 2026--Up 35% from 52 weeks ago , when it closed at $6.00--Down 10.99% from its 52-week closing high of $9.10 on Sept. 30, 2026--Up 51.97% from its 52-week closing low of $5.33 on Oct. 30, 2025--Traded as low as $7.98--Down 12.36% at today's intraday low; largest intraday percent decrease since Sept. 23, 2025, when it fell as much as 15.64%All data as of 12:12:14 PM ETSource: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672975961","title":"Eupraxia Pharmaceuticals Price Target Maintained with a $11.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2672975961","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672975961?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:41","pubTimestamp":1790851260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EPRX/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669498703","title":"Eupraxia Pharmaceuticals Initiated at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2669498703","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669498703?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:48","pubTimestamp":1790254080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EPRX/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669467696","title":"Eupraxia Pharmaceuticals Inc : Wedbush Initiates Coverage with Outperform Rating; Price Target $17","url":"https://stock-news.laohu8.com/highlight/detail?id=2669467696","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669467696?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:31","pubTimestamp":1790249486,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nFWN45G0X3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669646290","title":"Wedbush Initiates Eupraxia Pharmaceuticals at Outperform With $17 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2669646290","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669646290?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:04","pubTimestamp":1790247881,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (EPRX) has an average rating of buy and mean price target of $15.78, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143356","title":"H.C. Wainwright Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143356","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143356?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:45","pubTimestamp":1790070339,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brandon Folkes from H.C. Wainwright maintained a Buy rating on Eupraxia Pharmaceuticals, with a price target of $11...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-eupraxia-pharmaceuticals-eprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-eupraxia-pharmaceuticals-eprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378175","title":"Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378175","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378175?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868800,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Sept.  08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (Nasdaq: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveragi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357580/0/en/eupraxia-pharmaceuticals-completes-transfer-to-the-nasdaq-global-select-market-and-announces-participation-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664480982","title":"Eupraxia Pharmaceuticals management to meet with Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664480982","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664480982?lang=en_us&edition=fundamental","pubTime":"2026-09-04 02:40","pubTimestamp":1788460812,"startTime":"0","endTime":"0","summary":"Meeting to be held on September 9 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-management-to-meet-with-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-management-to-meet-with-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659545611","title":"Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2659545611","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659545611?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:00","pubTimestamp":1786622400,"startTime":"0","endTime":"0","summary":"The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post trea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344441/0/en/eupraxia-pharmaceuticals-reports-symptom-response-data-from-its-ongoing-phase-1b-2a-resolve-trial-including-new-data-on-odynophagia-painful-swallowing-in-eosinophilic-esophagitis-p.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658194647","title":"Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2658194647","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658194647?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:32","pubTimestamp":1786483947,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from the same period last","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61130473/eupraxia-pharmaceuticals-q2-eps-0-23-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658946271","title":"Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658946271","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658946271?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:21","pubTimestamp":1786483260,"startTime":"0","endTime":"0","summary":"New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster late","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/11/3343238/0/en/eupraxia-pharmaceuticals-reports-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657821016","title":"Eupraxia Pharmaceuticals files $300M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2657821016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657821016?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:17","pubTimestamp":1786011434,"startTime":"0","endTime":"0","summary":"06:12 EDT Eupraxia Pharmaceuticals (EPRX) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656745843","title":"David Martin Reiterates Buy on Eupraxia Pharmaceuticals, Citing Strong KOL Support for EP-104GI’s Commercialization Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2656745843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656745843?lang=en_us&edition=fundamental","pubTime":"2026-08-03 21:16","pubTimestamp":1785762964,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Martin PhD from Bloom Burton m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/david-martin-reiterates-buy-on-eupraxia-pharmaceuticals-citing-strong-kol-support-for-ep-104gis-commercialization-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/david-martin-reiterates-buy-on-eupraxia-pharmaceuticals-citing-strong-kol-support-for-ep-104gis-commercialization-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","KOL","BK4588","BK4139","XBI","LABU","BK4581","XLV","EP","BK4585","BK4213"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eupraxiapharma.com","stockEarnings":[{"period":"1week","weight":0.0378},{"period":"1month","weight":-0.156},{"period":"3month","weight":0.1824},{"period":"6month","weight":-0.0405},{"period":"1year","weight":0.2095},{"period":"ytd","weight":-0.0901}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.","exchange":"NASDAQ","name":"Eupraxia Pharmaceuticals","nameEN":"Eupraxia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eupraxia Pharmaceuticals(EPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eupraxia Pharmaceuticals,EPRX,Eupraxia Pharmaceuticals股票,Eupraxia Pharmaceuticals股票老虎,Eupraxia Pharmaceuticals股票老虎国际,Eupraxia Pharmaceuticals行情,Eupraxia Pharmaceuticals股票行情,Eupraxia Pharmaceuticals股价,Eupraxia Pharmaceuticals股市,Eupraxia Pharmaceuticals股票价格,Eupraxia Pharmaceuticals股票交易,Eupraxia Pharmaceuticals股票购买,Eupraxia Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eupraxia Pharmaceuticals(EPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}